idarucizumab
idarucizumab is a pharmaceutical drug with 7 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 6 completed trials
Phase Distribution
Phase Distribution
2
Early Stage
0
Mid Stage
4
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
85.7%
6 of 7 finished
14.3%
1 ended early
0
trials recruiting
7
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
This Study Looks at the Effects of Idarucizumab in Patients Who Take Dabigatran and Need Emergency Surgery or Are Bleeding
Observational Study to Evaluate Safety of Idarucizumab in Pediatric Patients
Reversal Dabigatran Anticoagulant Effect With Idarucizumab
Study to Investigate the Pharmacokinetics (PK) and Pharmacodynamics (PD) of Idarucizumab in Chinese Healthy Male and Female Volunteers Who Had Taken Dabigatran Etexilate and Whose Plasma Concentrations of Dabigatran Were at or Close to Steady State
CU Programme of Idarucizumab for Japanese Patients
Clinical Trials (7)
This Study Looks at the Effects of Idarucizumab in Patients Who Take Dabigatran and Need Emergency Surgery or Are Bleeding
Observational Study to Evaluate Safety of Idarucizumab in Pediatric Patients
Reversal Dabigatran Anticoagulant Effect With Idarucizumab
Study to Investigate the Pharmacokinetics (PK) and Pharmacodynamics (PD) of Idarucizumab in Chinese Healthy Male and Female Volunteers Who Had Taken Dabigatran Etexilate and Whose Plasma Concentrations of Dabigatran Were at or Close to Steady State
CU Programme of Idarucizumab for Japanese Patients
Reversal of Dabigatran Anticoagulant Effect With Idarucizumab
Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BI 655075 (Idarucizumab) Administered Alone or With Dabigatran Etexilate in Japanese Healthy Subjects
All 7 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 7